<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01593826</url>
  </required_header>
  <id_info>
    <org_study_id>3103010</org_study_id>
    <nct_id>NCT01593826</nct_id>
  </id_info>
  <brief_title>Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler</brief_title>
  <official_title>Pharmacokinetic Study Comparing Two Budesonide/Formoterol Fumarate Dihydrate Device-metered Dry Powder Inhalers, Budesonide/Formoterol Easyhaler 320/9 Microg/Inhalation and Symbicort Turbuhaler Forte; a Randomised, Double-blind, Single Centre, Single Dose, Crossover Study in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with
      the marketed product Symbicort Turbuhaler in terms of the drug absorbed into the bloodstream.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter Cmax of plasma budesonide concentration</measure>
    <time_frame>within 12 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter Cmax of plasma formoterol concentration</measure>
    <time_frame>within 24 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter AUCt of plasma budesonide concentration</measure>
    <time_frame>Within 12 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter AUCt of plasma formoterol concentration</measure>
    <time_frame>Within 24 h</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Charcoal and Symbicort Turbuhaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort Turbuhaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Charcoal and Budesonide/formoterol Easyhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide/formoterol Easyhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Charcoal and Budesonide/formoterol Easyhaler 320/9 microg</intervention_name>
    <description>2 inhalations as a single dose</description>
    <arm_group_label>Charcoal and Budesonide/formoterol Easyhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Charcoal and Symbicort Turbuhaler</intervention_name>
    <description>2 inhalations as a single dose</description>
    <arm_group_label>Charcoal and Symbicort Turbuhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/formoterol Easyhaler 320/9 microg</intervention_name>
    <description>2 inhalations as a single dose</description>
    <arm_group_label>Budesonide/formoterol Easyhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort Turbuhaler forte</intervention_name>
    <description>2 inhalations as a single dose</description>
    <arm_group_label>Symbicort Turbuhaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females aged 18-60 years.

          2. Normal weight, at least 50 kg.

        Exclusion Criteria:

          1. Evidence of a clinically significant cardiovascular, renal, hepatic, haematological,
             GI, pulmonary, metabolic-endocrine, neurological or psychiatric disease.

          2. Any clinically significant abnormal laboratory value or physical finding that may
             interfere with the interpretation of study results or constitute a health risk for the
             subject if he/she takes part in the study.

          3. Any condition requiring regular concomitant treatment (including vitamins and herbal
             products) or likely to need any concomitant treatment during the study.

          4. Known hypersensitivity to the active substance(s) or the excipient of the drug.

          5. Pregnant or lactating females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leena Mattila, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulla Sairanen, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orion Pharma Clinical Pharmacology Unit</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2012</study_first_submitted>
  <study_first_submitted_qc>May 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2012</study_first_posted>
  <last_update_submitted>November 21, 2012</last_update_submitted>
  <last_update_submitted_qc>November 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

